Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of wound healing gel I-020502 in autologous meshed skin grafting
2006-005092-18Phase 2Completed
- Sponsor
- Kuros Biosciences
- Start
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of KUR-212 in deep partial-thickness burn, burn injury and thermal injury (2 arms), sponsored by Kuros Biosciences. Primary endpoints: Incidence of treatment-related adverse events and Tolerability of I-020502 on wound healing. Started Dec 2006; status: completed.
02
Drugs
KUR-212
03
Conditions
deep partial-thickness burnburn injurythermal injury
Beyond the preview
Go deeper on 2006-005092-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005092-18.